Proteomics

Dataset Information

0

Proteomic analysis of genes regulated by miR-4510 in hepatocellular carcinoma


ABSTRACT: Patients with advanced hepatocellular carcinoma (HCC) are currently treated by Sorafenib and Regorafenib but efficacy of these multikinase inhibitors is disappointing. Thus, new drugs and therapies are needed to improve HCC management in clinic. We recently reported the remarkable capacity of miR-4510 to impede the growth of HCC and hepatoblastoma cells in vitro and in vivo through GPC3 targeting and Wnt pathway inactivation (Cartier F et al, Oncotarget 2017). Here, we used a label-free proteomic approach to identify new targets of miR-4510 in HCC-deriving Huh7 cells. We transfected HCC-derived Huh7 cells with either a synthetic miR-4510 mimic or a small RNA control, extracted total proteins 24hr later and comparatively analyzed proteomes of control and miR-4510-transfected cells using a quantitative label-free approach.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Hepatocellular Carcinoma

SUBMITTER: Dupuy Jean-William  

LAB HEAD: Grosset Christophe

PROVIDER: PXD010085 | Pride | 2019-10-23

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Linkbetweenfiles.xlsx Xlsx
RPS_2015_04_Homo_sapiens.fasta Fasta
fc150617_C1b.msf Msf
fc150617_C1b.raw Raw
fc150617_C2b.msf Msf
Items per page:
1 - 5 of 14
altmetric image

Publications

miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.

Ghousein Amani A   Mosca Nicola N   Cartier Flora F   Charpentier Justine J   Dupuy Jean-William JW   Raymond Anne-Aurélie AA   Bioulac-Sage Paulette P   Grosset Christophe F CF  

Liver international : official journal of the International Association for the Study of the Liver 20191031 1


<h4>Background</h4>Therapeutic outcomes using the multikinase inhibitors, sorafenib and regorafenib, remain unsatisfactory for patients with advanced hepatocellular carcinoma (HCC). Thus, new drug modalities are needed. We recently reported the remarkable capacity of miR-4510 to impede the growth of HCC and hepatoblastoma through Glypican-3 (GPC3) targeting and Wnt pathway inactivation.<h4>Methods</h4>To identify new targets of miR-4510, we used a label-free proteomic approach and reported down-  ...[more]

Similar Datasets

2020-12-31 | GSE152950 | GEO
2014-02-04 | E-GEOD-44079 | biostudies-arrayexpress
2014-04-01 | E-GEOD-56384 | biostudies-arrayexpress
2015-11-06 | E-GEOD-74710 | biostudies-arrayexpress
2014-02-04 | GSE44079 | GEO
2015-11-02 | E-GEOD-70178 | biostudies-arrayexpress
2018-03-29 | GSE97169 | GEO
2022-11-11 | PXD036643 | Pride
2017-01-17 | GSE78705 | GEO
2021-11-01 | GSE140148 | GEO